Patents by Inventor Michael P. McKenna

Michael P. McKenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180275140
    Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.
    Type: Application
    Filed: November 28, 2017
    Publication date: September 27, 2018
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20180267053
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 or less of a legacy clinical sample.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 20, 2018
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Publication number: 20180024143
    Abstract: The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.
    Type: Application
    Filed: October 2, 2017
    Publication date: January 25, 2018
    Inventors: Michael P. McKenna, Steven M. Watkins
  • Patent number: 9810697
    Abstract: The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: November 7, 2017
    Assignee: True Health IP, LLC
    Inventors: Michael P. McKenna, Steve M. Watkins
  • Publication number: 20170316153
    Abstract: A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbA1c; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventors: Michael P. McKenna, Michael Rowe, Edward J. Moler, JR., Robert W. Gerwien
  • Publication number: 20170261520
    Abstract: Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9740819
    Abstract: A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: August 22, 2017
    Assignee: TRUE HEALTH IP LLC
    Inventors: Michael P. McKenna, Michael Rowe, Edward J. Moler, Jr., Robert W. Gerwien
  • Publication number: 20170205430
    Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9689880
    Abstract: Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: June 27, 2017
    Assignee: TRUE HEALTH IP LLC
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20170003297
    Abstract: The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.
    Type: Application
    Filed: November 18, 2015
    Publication date: January 5, 2017
    Inventors: Michael P. McKenna, Steve M. Watkins
  • Publication number: 20160139139
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L. or less of a legacy clinical sample.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 19, 2016
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Patent number: 9217747
    Abstract: The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: December 22, 2015
    Assignee: Health Diagnostic Laboratory, Inc.
    Inventors: Michael P. McKenna, Steve M. Watkins
  • Publication number: 20150346218
    Abstract: Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
    Type: Application
    Filed: May 5, 2015
    Publication date: December 3, 2015
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20150193587
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Application
    Filed: December 3, 2014
    Publication date: July 9, 2015
    Inventors: Mickey S. URDEA, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9057736
    Abstract: Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: June 16, 2015
    Assignee: Health Diagnostics Laboratory, Inc.
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9034585
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: Health Diagnostic Laboratory, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20140147850
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 29, 2014
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20140072571
    Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.
    Type: Application
    Filed: March 11, 2013
    Publication date: March 13, 2014
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20130267442
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
    Type: Application
    Filed: January 21, 2013
    Publication date: October 10, 2013
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Patent number: 8409816
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: April 2, 2013
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf